Table 8 Deterministic sensitivity analyses of parameters that have a large effect on the model results
Total hip replacement | Total knee replacement | |||||||
|---|---|---|---|---|---|---|---|---|
Incremental events | Incremental costs (hospital) | Incremental costs (SHI) | ICER (SHI) | Incremental events | Incremental costs (hospital) | Incremental costs (SHI) | ICER (SHI) | |
Base case | 0.0070 | 31.8 | 18.0 | 2,569.3 | 0.0203 | 20.7 | −27.2 | dominance |
Probability that a VTE event is a DVT during prophylaxis with enoxaparin (Parameter 4) | ||||||||
0.90 0.95 0.99 | 0.00850.00730.0064 | 31.431.732.0 | 15.017.419.3 | 1,762.72,364.33,006.6 | 0.03220.02440.0181 | 6.215.723.4 | −49.9−35.0−23.0 | dominancedominance dominance |
Probability that a DVT is symptomatic during prophylaxis with enoxaparin (Parameter 6) | ||||||||
0.090.170.26 | 0.00490.00710.0095 | 32.631.830.9 | 21.017.914.5 | 4,244.12,523.91,521.3 | 0.01470.02860.0443 | 24.215.55.8 | −21.8−35.3−50.4 | dominance dominance dominance |
Probability that an asymptomatic DVT becomes symptomatic (Parameter 7) | ||||||||
0.010.150.60 | 0.00270.00590.0160 | 31.831.831.8 | 26.320.20.7 | 9,570.33,428.341.9 | 0.01750.02790.0613 | 20.720.720.7 | −21.4−42.893.2 | dominance dominance 1520.0 |
Probability that a DVT is symptomatic during prophylaxis with rivaroxaban (Parameter 12) | ||||||||
0.060.160.50 | 0.00820.00760.0055 | 31.431.632.4 | 16.517.320.0 | 2,026.22,291.63,626.0 | 0.11230.10320.0723 | 18.524.143.0 | −30.6−21.88.2 | dominance dominance 113.3 |
Prophylaxis costs with enoxaparin in the case of post-discharge VTE or no VTE and no ME (Parameter 14) | ||||||||
20% lower20% higher | 0.00700.0070 | 31.8 31.8 | 39.2−3.2 | 5,592.5dominance | 0.0203 0.0203 | 20.7 20.7 | −26.9−27.5 | dominance dominance |
Prophylaxis costs with rivaroxaban in the case of post-discharge VTE or no VTE and no ME (Parameter 17) | ||||||||
20% lower20% higher | 0.00700.0070 | 25.438.3 | −8.944.9 | dominance6,402.5 | 0.02030.0203 | 14.227.2 | −27.6−26.8 | dominance dominance |